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Abstract
Background: New technologies for acquisition of genomic data, while offering unprecedented opportunities for genetic
discovery, also impose severe burdens of interpretation andpenalties for multiple testing.
Methods: The Pathway-based Analyses Group of the Genetic Analysis Workshop 19 (GAW19) sought reduction of
multiple-testing burden through various approaches to aggregation of highdimensional data in pathways informed by
prior biological knowledge.
Results: Experimental methods testedincluded the use of "synthetic pathways" (random sets of genes) to estimate power
and false-positive error rate of methods applied to simulated data; data reduction via independent components analysis,
single-nucleotide polymorphism (SNP)-SNP interaction, and use of gene sets to estimate genetic similarity; and general
assessment of the efficacy of prior biological knowledge to reduce the dimensionality of complex genomic data.
Conclusions: The work of this group explored several promising approaches to managing high-dimensional data, with
the caveat that these methods are necessarily constrained by the quality of external bioinformatic annotation.
Background
The data provided for Genetic Analysis Workshop 19
(GAW19) offer extensive and complex genomic information
(described fully in Blangero et al. [1]). These data included 2
Mexican American cohorts: a set of extended families provid-
ing longitudinal data on blood pressure (BP; up to 4 clinic
visits per subject) and genomic data including haplotype-
tagging single nucleotide polymorphisms (SNPs) and whole
sequence data for odd-numbered autosomes, as well as gene
expression profiles from the first clinic visit; and a separate
set of unrelated individuals with BP and exome sequence
data from a single clinic visit. The GAW19 organizers also
provided 200 replicates of simulated BP data for both cohorts
based on the real genotypes and a polygenic generating
model using functional variants in genes chosen based on
real associations between BP and gene expression phenotypes
in the Type 2 Diabetes Genetic Exploration by Next-
generation sequencing in Ethnic Samples (T2D-GENES)
study ([1]). This rich genomic resource serves as a sampler of
the types of data now becoming available for many study
cohorts as a result of rapid technological advances (and
attendant decreased costs) in acquisition of genomic
information.
For GAW19, as in all such studies, this abundance is
both a blessing and a curse, a potential source of new in-
sights into the mechanisms of complex disease phenotypes
that also introduces an unprecedented burden of
correction for multiple tests and interpretation of results.
A class of emerging techniques for managing this abun-
dance involves narrowing the search space by grouping the
units of analysis (gene expression probes, sequence vari-
ants, etc) into biologically relevant pathways (see, eg, Wang
et al [2] for a review of software for pathway analysis to fol-
low genome-wide association studies [GWAS]). Pathway
analysis can proceed along at least 2 general lines [3]:
1. Preselection of biological pathways believed to be
relevant to the disease or phenotype of interest. The
primary goals of this approach are to limit the
number of genomic features, and therefore the
multiple-testing burden, to those annotated to genes
in the candidate pathways, and/or to confirm the
prior biological hypotheses. An additional aim is to
manage genetic heterogeneity: for example, different
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lineages may segregate variation in different genes in
the same pathway that nonetheless yield similar
biological effects. Without prior biological knowledge,
this heterogeneity might be interpreted as noise rather
than as concordant signal [4].
2. Gene enrichment tests of genomic features
prioritized by evidence of association with the
phenotype of interest to identify biological pathways
a posteriori. The primary goal of this approach is to
interpret the biological significance of findings from
agnostic tests of association.
Both of these lines of investigation are constrained by
existing biological knowledge (and by the curation strat-
egies and quality of available bioinformatic databases).
Because pathway analysis is relatively new, methods
for assigning genomic features to pathways and for
testing the significance of these assignments in relation
to phenotypes are still very much under development.
This developmental fluidity was the context for this
discussion group at GAW19.
Methods
This report is based on the work of 7 research teams who
presented their work in our group discussion at GAW19.
In the following discussion, these teams are referenced by
the name of the presenting author, as shown in Table 1.
Tables 2 and 3 summarizes the teams’ approaches to
the group topic, including the focal phenotypes chosen
from the GAW19 data, the focal genomic feature (gene
expression or genetic variants), and the analytical tools
employed. These choices, which were intimately associ-
ated with each team’s primary aims, are compared and
discussed in detail under Results.
Results and discussion
Motivation
An overriding motivation for employing pathway analysis
was to reduce the multiple-testing burden by basing infer-
ences on the combined effects of probes or variants. Most
teams used external bioinformatic data to inform pathway
construction (see Table 3). However, the use of pathways
to clarify biological function or interpret association re-
sults, while highly relevant to future applications of these
methods, was a secondary concern given the method-
development focus of these studies. Of all the studies,
Ziyatdinov came closest to this interpretive approach,
using relationships in the data to recover the biological
processes implicit in the simulation generating model.
Data selection; pathway assembly
All teams used the BP data (real or simulated) provided
for GAW19, including systolic (SBP) and diastolic BP
(DBP) and hypertension (HT) status. Several teams also
calculated the derived phenotype mean arterial pressure
(MAP) from these data as (2/3 DBP + 1/3 SBP). All teams
using the simulated data chose not to be blind to the
generating model (they “used the answers”), which
allowed them to estimate power to detect “true” functional
variants and associated gene expression phenotypes. Most
teams also used the provided null trait Q1 to estimate type
1 error rate. A limitation of this use of the simulated data
(as noted by a reviewer of an early draft of this report) is
that evaluation of method performance is necessarily
sensitive to the assumptions of the generating model.
Three teams (Brunel, Quillen, Ziyatdinov) focused on the
gene expression probes, while the remaining teams consid-
ered single nucleotide variants (SNVs) drawn from the
GWAS genotypes, exome sequence data, or both. Com-
bined analysis of gene expression and association has been
considered in previous GAWs (eg, Charlesworth et al. [5]),
but only Brunel attempted this combination in a 2-step
approach (data reduction of BP-related gene expression
phenotypes followed by GWAS).
As noted, most teams made use of the simulated pheno-
types as a basis for estimating power and type 1 error. Kos,





Brunel H Meta-expression: A methodology for
the joint analysis of gene expression
in biological pathways.
Massanet R, Fernández-Albert F,
Ziyatdinov A, Soria JM, Perera A
Unpublished
Kos MZ Comparison of GWAS and exome
sequence data sets from GAW19.
Blackburn AN, Almasy L
Unpublished
Lo A Network-guided interaction mining for
blood pressure phenotype of unrelated
individuals in GAW19.
Agne M, Auerbach J, Fan R, Lo S-H,
Wang P, Zhang T
Unpublished
Quillen EE A variance component method for
integrated pathway analysis of gene
expression data.
Blangero J, Almasy L
[13]
Tayo BO Association of polymorphisms in
the aldosterone-regulated sodium
reabsorption pathway with blood
pressure among Hispanics.
Tong L, Cooper RS
[11]
Valcarcel A A hierarchical approach to SNP-set
analysis: An evaluation of power and
type 1 error of gene-based tests of
association after pathway-based analysis.
Grinde K, Cook K, Green A, Tintle N
[9]
Ziyatdinov A Prioritization strategies in enrichment
analysis of gene expression data in
GAW19 family-based study.
Fernández-Albert F, Vazquez-Santiago M,
Soria JM, Perera-Lluna A
unpublished
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Quillen, and Valcarcel constructed synthetic pathways
(described more fully below) of gene expression probes
(Quillen) or SNVs (Kos, Valcarcel) representing predeter-
mined numbers of randomly chosen genes; these synthetic
pathways were then characterized by the number of genes
that contributed to the simulated phenotypes as a basis for
measuring the effect of functional “dosage” on analytical
power. One team (Tayo) focused on a single biological path-
way with known relevance to hypertension (aldosterone-reg-
ulated sodium reabsorption), using both real and simulated
BP phenotypes.
Kos, Quillen, and Valcarcel independently conceived of
using sets of probes or variants annotated to randomly se-
lected genes to define synthetic pathways (SPs) to test both
the power and type 1 error of their proposed methods. SPs
that represented genes used in the simulation generating
model were, in Quillen’s terminology, “positive controls” to
test the sensitivity of tests. SPs lacking such representation
provided data on false positive rate, either in place of or
supplementary to tests of the null trait Q1. All 3 teams used
various metrics—for example, number of genes represented
in each SP or number of generating-model genes
represented—to further characterize the performance of
their analytical approaches.
In addition to the dimensional reduction achieved by
grouping probes or variants in pathways, some teams also
filtered variants based on predicted function (eg, Kos).
Lo developed biological pathways nominally based on a hy-
pothesis that hypertension could be related to undetected
type 2 diabetes (this is known to have elevated prevalence in
the Mexican American cohorts from which the GAW19 data
were derived, but diabetes status was not reported as part of
the provided data set). Pathway construction consisted of
choosing a set of diabetes-related genes from the literature
and then expanding these “seed” genes with publicly available
gene interaction data. In the context of this workshop, this
approach simply provided a biologically plausible way to con-
struct pathways reflecting the number of genes and patterns
of gene–gene interaction that might be encountered in a
“real” study; this was tangential to the primary goal of charac-
terizing performance of these investigators’ bespoke method
for analyzing SNP-SNP interaction effects [6] (see below).
As noted, most pathways were user-defined, either
based on numbers of genes (to test effects on power and
Table 2 Summary of research approaches: Data used
Contribution Genomic data Cohort Phenotype category Phenotype(s)
Brunel Gene expression/GWAS Families Real (gene expression) Deriveda
Kos GWAS and exomic variants Families Simulatedb DBP (first visit)
Lo GWAS and exomic variants Unrelated Real DBP (first visit)
Quillen Gene expression Families Simulatedb DBP (first visit)
Tayo GWAS and exomic variants Unrelated Simulatedb and real DBP, SBP, HT, MAP
Valcarcel GWAS and exomic variants Families Simulatedb Means across visits of DBP, SBP, HT, MAP
Ziyatdinov Gene expression Families Real SBP
DBP diastolic blood pressure; GWAS, genome-wide association studies; HT hypertension; MAP mean arterial pressure; SBP, systolic blood pressure
aIndependent components (see Table 3 and text)
bAuthors were aware of simulation model “answers”
Table 3 Summary of research approaches: Analytical strategies
Contribution Pathway assembly Probe/variant filters Source of annotations/ biological
significance
Analytical tools




Gene Ontology, other (unspecified) Independent components
analysis, GWAS in GenABEL
Kos Synthetic Nonsynonymous or stop
codon gain/loss




Lo Annotated to type 2 diabetes
genes and interactors
Not applicable OMIM, GeneMania Bespoke method to detect SNP-
SNP interaction
Quillen Synthetic Not applicable Ariadne Pathway Studio 8.0 Empirical similarity matrices,
variance decomposition





Valcarcel Synthetic Not reported ANNOVAR SKAT, burden tests
Ziyatdinov Associated with BP Heritability Gene Ontology Linear mixed models
ANNOVAR Annotate Variation; BP blood pressure; GWAS genome-wide association studies; KEGG Kyoto Encyclopedia of Genes and Genomes; OMIM Online Mendelian
Inheritance in Man; SKAT sequence kernel association test; SNP single nucleotide polymorphism; SOLAR Sequential Oligogenic Linkage Analysis Routines
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specificity) or on prior biological information, rather
than on empirical networks (eg, by weighted correlation
networks) [7]. This was consistent with the emphasis on
methodological development, especially on data reduc-
tion and control of the burden of multiple testing. The
known causal structure of the simulated data might have
supported a test of the efficacy of an empirical networks
approach to recover the generating model from patterns
of SNV association, but no team attempted this.
Analytical tools
The focus for methodological innovation in these studies
was typically on the construction or definition of path-
ways. In general, established tools were used for relating
pathway-defined probes or variants to the traits of inter-
est, accounting for family data where appropriate: for ex-
ample, variance components-based analyses implemented
in SOLAR (Sequential Oligogenic Linkage Analysis
Routines) [8], by Kos and Quillen; adaptation of SKAT
(sequence kernel association test) by Valcarcel; burden
tests [9]; GenABEL [10] by Brunel; and PLINK for un-
related data [11].
An exception to this pattern was the use by Lo of an
analytical tool to detect gene interactions, previously de-
veloped by members of this team [6]. In brief, this
method involves comparing the joint effect of 2 SNPs on
a trait to the marginal effect of each; a ratio of joint to
marginal effects significantly greater than 1 (as assessed
by permutation) is taken as evidence of SNP–SNP inter-
action effects on the phenotype [6]. Using pairwise tests
of SNPs annotated to genes in a pathway of interest
(described above), these authors reported evidence of
a joint effect of variants in GCK and PAX4 on hyperten-
sion (real data from the unrelated cohort). As noted by
the anonymous reviewers of these authors’ report, the na-
ture of this joint effect—whether due to in-sample LD,
interaction between the gene products, or some other
effect—needs additional investigation.
Gene expression
We now consider selected approaches in more detail.
Taking replicate simulations of DBP as the trait of interest,
Quillen analyzed the random effect of similarity in gene
expression among related individuals, with the goal of
identifying pathways for which coexpression accounted
for a significant proportion of variance relative to model-
ing the random effect of kinship alone. This analysis com-
pared the effect of 16 methods for computing similarity
matrices from the expression data; of these, simple correl-
ation and extended Jaccard distance [12] outperformed
the others and greatly exceeded the performance of
single-probe association as a consequence of reduced mul-
tiple testing. As expected, performance was dependent on
the number of genes in the SPs that contributed by design
to the simulated phenotypes [13].
Brunel developed pathways based on probes in the
GAW19 data that were annotated to genes related to BP
in Gene Ontology, or to genes related to these by pub-
lished evidence of protein–protein interaction. They
then used independent components analysis (ICA) to
derive “meta-expression” phenotypes (ICA factors). Un-
fortunately, the use of phenotypes derived from the real
gene expression data, rather than simulated data, pre-
vented estimation of power and type 1 error rate, so it
was not possible to determine if any increase in signal
from data reduction could overcome the multiple-
testing burden inherent in GWAS.
Single nucleotide variants
Valcarcel proposed 2-step association tests of a simu-
lated BP phenotype that consisted of variant aggregation
(via either SKAT or burden test) for all variants in a
pathway, followed by gene-centric aggregation tests
within pathways that passed a chosen significance
threshold. Their pathways were synthetic (randomly
chosen sets of specified numbers of genes with retention
of pathways that contained at least 1 gene that was
causal in the simulation). The 2-step approach was more
powerful, with reasonable control of type 1 error, than a
1-step gene-centric approach because of the reduction
in multiple testing by prescreening of pathways.
Conclusions
A primary focus in the Pathway-based Analyses Group
was on managing the very large dimensionality of -omics
data to increase analytical power. As noted in the
Introduction, pathway analysis can also be employed
for biological discovery, although this use was not
focal for participants in this discussion group. Meth-
odology for this sort of discovery is also in its infancy
and would also be a worthy topic for future investiga-
tion, although provision of optimal simulation data
for this purpose (eg, simulated gene expression data)
would be a major challenge.
Because many pathway-based approaches, including the
pathway construction carried out by participants in this
group, are heavily dependent on bioinformatic databases,
our group discussions frequently returned to concerns
about the current state of these resources, no matter how
well curated – including inaccuracies, difficulty of inter-
pretation, and (inevitably) publication bias. This suggests a
possible contradiction at the heart of pathway analysis
(which, regrettably, we did not discuss): many of our
studies used pathway aggregation to reduce the multiple-
testing burden that hampers gene and variant discovery,
yet pathway construction based on prior knowledge runs
the risk of constraining the scope of discovery. A possible
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way out of this dilemma, as noted above, is to search for
empirical networks that may reveal unexpected gene
interactions and thus novel biological insight.
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